---
title: "AlphaPai’s $50M Series B: Insurance and Broker Capital Buy Research AI"
description: "Hong Kong’s AlphaPai raised $50M Series B on September 15, 2026 — its third round in a year — with China Insurance Investment and GF Securities’ PE arm joining Qiming and others. Company: 120,000+ professional users across 8,000+ institutions."
date: 2026-09-15T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-alphapai-50m-series-b-china-insurance-financial-ai
---

# AlphaPai’s $50M Series B: Insurance and Broker Capital Buy Research AI

> Hong Kong’s AlphaPai raised $50M Series B on September 15, 2026 — its third round in a year — with China Insurance Investment and GF Securities’ PE arm joining Qiming and others. Company: 120,000+ professional users across 8,000+ institutions.

**[AlphaPai](/startup/alphapai)** (Rabyte Technology) closed a **$50 million Series B** on **September 15, 2026** — its **third** financing in roughly a year — with **China Insurance Investment** and **GF Xinde** (GF Securities’ PE arm) joining **Qiming Venture Partners**, **Ambrum**, **Next Capital**, **Trustar**, **Eastern Bell**, and existing holders ([PR Newswire Asia](https://en.prnasia.com/releases/apac/alphapai-raises-us-50-million-in-series-b-funding-as-financial-ai-moves-into-the-depths-of-professional-work-547872.shtml)).

Financial AI is raising into **workflow ownership** — not meeting bots — and the syndicate is dominated by **industry capital that buys the product category**.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [AlphaPai](/startup/alphapai) — Hong Kong; AI investment research |
| Round | **$50M** Series B; **3rd** round in ~1 year; valuation **n/d** |
| Strategic anchors | China Insurance Investment; GF Xinde (GF Securities) |
| Other named | Qiming, Ambrum, Next Capital, Trustar, Eastern Bell + existing |
| Advisor | China Renaissance (exclusive FA) |
| Traction (company) | **120,000+** professional users; **8,000+** institutions |
| Product | AlphaPai assistant; **PaiWork** workstation (Apr 2026); iRaB benchmark; ORE partner program (**40+** institutes) |

*None of these investors sit in our `/fund/` directory — editorial names only.*

## Who uses the product — and for what job

**Users:** Professional investors inside banks, brokers, asset managers, and insurance investment teams who live in meetings, filings, models, and knowledge bases.

**Job today:** Move from high-frequency AI assists (meetings, information processing) into **core research production** — analysis, institutional knowledge, multi-asset workflows inside PaiWork.

**Job next:** Deeper insurance and multi-asset coverage, supply-chain collaboration with data/broker partners, and a measured overseas push after proving the China institutional density story.

## Why now

- Generic LLM chat lost the “wow” premium; institutions pay for **workflow + compliance-shaped** research environments.
- Insurance capital and securities PE joining the cap table is distribution and credibility for regulated research use cases.
- Third round in a year implies either rapid product adoption or a hot Asia financial-AI window — diligence which.

## Why these funds — portfolio fit

**China Insurance Investment** is not a tourist check: insurance portfolios span equities, fixed income, and alternatives with long research chains. Owning a stake in the research assistant that might sit inside those chains is strategic co-creation, not only financial IRR.

**GF Xinde / Guanggu-linked capital** explicitly incubates advisory-ecosystem fintech — AlphaPai sits in the “service provider” layer of that thesis.

**Qiming** and the other named VCs provide classic venture scaffolding around industrial capital so the round is not only strategic soft money.

## Competitive map

| Approach | Tradeoff |
| --- | --- |
| Horizontal copilots (ChatGPT Enterprise, etc.) | Flexible; weak finance-native data/eval loops |
| Incumbent terminal add-ons | Distribution; slower agent/workstation UX |
| Meeting-only fintech AI | Clear wedge; stalls before research core |
| AlphaPai PaiWork + ecosystem (iRaB/ORE) | Workflow depth; China-market concentration risk |

## What is not proven

- Valuation, prior round sizes, and revenue / ARR.
- Independent verification of **120k users / 8k institutions** and “tens of times” token growth claims.
- Overseas traction beyond stated ambition.

## Practical takeaway

- **Founders (fintech AI):** Industrial capital that **uses** your category can outrank logo VCs on Series B — if you already sit in production workflows.
- **Investors:** Diligence user quality (licensed PMs vs free seats) and whether insurance/broker shareholders create pull-through or channel conflict.
- **Allocators / researchers:** Relevant if you need a China-native research workstation story; treat global claims as forward-looking.

### Sources

1. [PR Newswire Asia — AlphaPai $50M Series B](https://en.prnasia.com/releases/apac/alphapai-raises-us-50-million-in-series-b-funding-as-financial-ai-moves-into-the-depths-of-professional-work-547872.shtml)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.